STOCK TITAN

Exact Sciences Corp. - EXAS STOCK NEWS

Welcome to our dedicated news page for Exact Sciences (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exact Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exact Sciences's position in the market.

Rhea-AI Summary
Exact Sciences Corp. collaborates with Mayo Clinic to develop a non-endoscopic screening tool for esophageal adenocarcinoma and its precursors, showing high sensitivity and specificity in detecting early stages of the cancer. The test aims to address the critical need for screening in high-risk populations, with potential to revolutionize esophageal cancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. (EXAS) receives the 2024 Gallup Exceptional Workplace Award for its engaged workplace culture, highlighting dedication to teamwork, well-being, and professional growth. The company's employee engagement ratio surpasses global averages, emphasizing its commitment to eradicating cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. announces the online publication of the BLUE-C study results in The New England Journal of Medicine, showcasing the performance of their next-generation multitarget stool DNA test, Cologuard Plus, for colorectal cancer screening. The study demonstrated 94% sensitivity for CRC at 91% specificity, outperforming the fecal immunochemical test. Cologuard Plus aims to reduce unnecessary follow-up colonoscopies and is set to be available in 2025 pending FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
none
Rhea-AI Summary
Exact Sciences Corp. collaborates with The Blue Hat Foundation to launch 'Box Out Colon Cancer' campaign with Jamal Mashburn, promoting colorectal cancer screening and prevention during Colorectal Cancer Awareness Month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.22%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. (EXAS) to participate in TD Cowen 44th Annual Health Care Conference with a fireside chat on March 4, 2024. Investors invited to join via webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences Corp. reports record revenue, positive free cash flow, and expects 2024 revenue of $2.810-2.850 billion. The fourth quarter and 2023 highlights include total revenue of $647 million, a 17% increase, with Screening revenue at $487 million and Precision Oncology revenue at $160 million. The company's financial results showcase growth in both revenue and cash flow, reflecting a strong performance in cancer screening and diagnostic tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
earnings
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) plans to release its fourth quarter 2023 financial results on February 21, 2024, followed by a webcast and conference call to discuss financial results and business progress. The webcast and call will be open to all interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
earnings
-
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, and submits next-generation Cologuard to FDA. The company also announces Chief Financial Officer succession plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
earnings
-
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) will participate in the J.P. Morgan Healthcare Conference on January 8, 2024, at 2:15 p.m. ET, with a webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
conferences
Rhea-AI Summary
Exact Sciences (EXAS) awarded $1.3 million to 23 organizations through its FOCUS Program to improve colorectal cancer screening rates. Since 2022, the program has awarded $2.9 million to 50 organizations. The company developed Cologuard, the first FDA-approved noninvasive screening test, and has delivered over 13 million results since 2014.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Exact Sciences Corp.

Nasdaq:EXAS

EXAS Rankings

EXAS Stock Data

12.54B
179.55M
1.01%
89.48%
3.59%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
US
Madison

About EXAS

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com